Christian P. Pavlovich, MD, presented “Secondary Biomarkers for Prostate Cancer Clinical Overview 2025” during the 35th International Prostate Cancer Update conference on February 9, 2025, in Vail, Colorado.

This content is available free to the GRU Community. Login or create an account to view it.

Login

Create an Account

How to cite: Pavlovich, Christian P. “Secondary Biomarkers for Prostate Cancer Clinical Overview 2025.” February 9, 2025. Accessed Jul 2025. https://grandroundsinurology.com/secondary-biomarkers-for-prostate-cancer-clinical-overview-2025/

Secondary Biomarkers for Prostate Cancer Clinical Overview 2025 – Summary

Christian P. Pavlovich, MD, Bernard L. Schwartz Distinguished Professor in Urologic Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, provides a detailed overview of serum and urinary biomarkers for prostate cancer diagnosis and prognosis. In this 15-minute presentation, Dr. Pavlovich advocates for personalized approaches that leverage biomarkers, genetic insights, and advanced predictive tools to improve prostate cancer detection and reduce unnecessary interventions.

Dr. Pavlovich highlights biomarkers such as PHI, 4KScore, IsoPSA, SelectMDx, MyProstateScore, and ExoDx Prostate Test (EPI) that offer improved specificity in identifying clinically significant prostate cancer. Risk calculators like the PCPT, ERSPC, and PBCG provide individualized risk assessments and can guide clinical decisions. 

Dr. Pavlovich encourages using online calculators for improved accuracy in predicting biopsy outcomes. He also introduces emerging genomic tests, polygenic risk scores, and comprehensive platforms like Stockholm3 that integrate biomarkers, clinical data, and genetics. In addition, combining biomarkers with MRI and clinical information enhances diagnostic accuracy.

About the 35th International Prostate Cancer Update:

The International Prostate Cancer Update (IPCU), is a multi-day, CME-accredited conference focused on new developments in prostate cancer treatment, diagnosis, and prevention. IPCU 35 will feature lectures, interactive discussions, panel roundtables, debates, and case reports. This conference is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer.

The goal of this educational program is to equip healthcare professionals involved in the diagnosis and treatment of prostate cancer with the up-to-date clinical knowledge and tools they need to best treat their patients. The program will discuss the treatment of prostate cancer from diagnosis to treating advanced and metastatic disease. The conference aims to give physicians exposure to a comprehensive review of treating prostate cancer patients and to give them a chance to discuss the issues with peers and experts. You can learn more about the conference here.

ABOUT THE AUTHOR

+ posts

Dr. Christian P. Pavlovich is a renowned urologist specializing in urologic oncology, focusing on prostate and kidney cancers. He is the Bernard L. Schwartz Distinguished Professor in Urologic Oncology at Johns Hopkins University School of Medicine and directs the Prostate Cancer Active Surveillance Program. Dr. Pavlovich is known for his expertise in minimally invasive and robotic surgeries, as well as his pioneering work in cancer detection and active surveillance strategies. He is dedicated to providing personalized, high-quality care to patients with urologic cancers.